Trial reportDrug design, development and therapy2025
Tegileridine versus Oliceridine for Acute Postoperative Pain Management in Patients After Minimally Invasive Esophagectomy: A Preliminary Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluation of the efficacy and safety of tegileridine at different doses in patients with postoperative pain: a meta-analysis of randomized controlled trials.Frontiers in pain research (Lausanne, Switzerland) · 2026Pooled it
- Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.Annals of medicine · 2026Trial
- Determination of the ED50 of Tegileridine and Comparison with Fentanyl for Analgesia During Hysteroscopy in Chinese Female Patients: An Exploratory Sequential Dose‑Finding Study.Drug design, development and therapy · 2026Trial
- Tegileridine versus Sufentanil for Patient-Controlled Intravenous Analgesia After Cesarean Delivery: A Randomized Double-Blind Trial.Drug design, development and therapy · 2026Trial
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Tegileridine, a new highly selective biased µ-opioid receptor agonist, demonstrated a favorable profile in relief of moderate-to-severe pain, but comparative data with other µ-opioid receptor agonists are sparse. We aimed to compare the analgesic efficacy of tegileridine to oliceridine with morphine as the active control in patients undergoing minimally invasive esophagectomy (MIE). Patients and Methods: We conducted a preliminary randomized trial involving patients having moderate-to-severe pain after MIE. Patients were randomized 2:2:1 to receive a loading dose of 0.75 mg tegileridine, 1.5 mg oliceridine, or 3 mg morphine, followed by a patient-controlled analgesia pump composed of the corresponding same agent over a 48-hour period. The primary endpoint was the time-weighted sum of the resting pain-intensity difference over 24 hours (rSPID Results: A total of 75 patients were randomized and finally analyzed (n = 15 in morphine group, n = 30 in tegileridine and oliceridine groups). Neither the time-weighted rSPID Conclusion: Tegileridine showed comparable or slightly superior analgesic efficacy to oliceridine for moderate-to-severe pain following MIE. These findings support that tegileridine may provide promising profiles for postoperative pain management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.